Alembic Ltd Stock Price Today (NSE: ALEMBICLTD)

Alembic Ltd

90.79+1.54 (+1.73%)
Market Closed

Fundamental Score

...

Alembic Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis

Alembic Ltd share price today is 90.79, up +1.73% on NSE/BSE as of 17 June 2026. Alembic Ltd (ALEMBICLTD) is a Small-cap company in the Residential, Commercial Projects sector with a market capitalisation of 2.57K (Cr). The 52-week high for ALEMBICLTD share price is 125.54 and the 52-week low is 70.46. At a P/E ratio of 7.95x, ALEMBICLTD is currently trading below its industry average P/E of 35.86x. The company has a Return on Equity (ROE) of 13.69% and a debt-to-equity ratio of 0.00.

Alembic Ltd Share Price Chart — NSE/BSE Historical Performance

No data
High
96.37
Low
86.02
Volume
2.1L
Change
-5.82%

Alembic Ltd share price chart: -5.82% return over the past month. 52-week high ₹125.54, 52-week low ₹70.46.

Alembic Ltd — Last 10 Trading Days

DateOpenHighLowCloseVolume
86.4188.2885.8687.351.82L (Cr)
88.9588.9585.7686.651.89L (Cr)
87.4088.9087.2687.642.77L (Cr)
88.1288.1286.9787.132.56L (Cr)
87.6288.8987.5187.911.71L (Cr)
88.1989.5086.5087.623.13L (Cr)
87.0388.1087.0387.341.37L (Cr)
88.7589.7687.0687.411.72L (Cr)
87.0088.5786.0287.273.71L (Cr)
88.5591.2688.5589.841.79L (Cr)

Alembic Ltd — Last 12 Months Price History

MonthOpenHighLowCloseChange
88.9588.9585.7687.35-1.80%
91.2096.3786.0287.64-3.90%
72.0995.0072.0991.20+26.51%
86.8091.0070.4670.90-18.32%
92.20100.8789.9091.72-0.52%
101.19105.0089.8092.93-8.16%
100.00106.3994.83101.19+1.19%
99.50103.4097.38100.04+0.54%
99.78104.2896.3199.40-0.38%
101.53108.5099.4099.78-1.72%
112.00114.80100.50101.53-9.35%
124.70124.70110.56112.12-10.09%

AI Research Briefing

Powered by Gemini · 2026-04-17

Alembic is a generics grinder; steady execution, not explosive growth, is the name of the game.

Research Confidence
6.0/10Moderate
COMPOUNDERNegative. 1M: 0.82%, 3M: -3.37%, 6M: -9.43%.Fair. P/E is 7.95x vs Industry P/E of 35.86x.

WHAT'S HAPPENING NOW (last 2-4 weeks)

Alembic Pharma received USFDA final approval for Methotrexate Injection. The approval covers both multi-dose (50 mg/2 mL) and single-dose (1 g/40 mL) formats. Alembic Pharma also launched its second 100-day 'Saksham Niveshak' campaign to facilitate dividend claims and KYC updates for shareholders.

CORE STORY (THE REAL GAME)

Alembic is a play on steady, if unspectacular, US generics approvals. They're building a diversified portfolio to de-risk reliance on any single blockbuster drug. Not a high-growth story, but a grind-it-out generics business.

Why Now
  • USFDA approval for Methotrexate Injection
  • Focus on regulated markets and injectables
  • Saksham Niveshak campaign to facilitate dividend claims
Potential Catalysts
  • Faster than expected USFDA approvals
  • Successful penetration of the injectables market
  • Acquisition of a strategic asset
Key Risks
  • Negative free cash flow
  • Intense pricing pressure in US generics market
  • Compliance risk in regulated markets
Institutional Activity

FII decreased holdings by 0.12%.

Macro Context

Real estate market is seeing record-breaking deals and soaring demand for luxury homes.

Cash Flow Quality

No. Free Cash Flow 5Y: ₹-84.37 Cr

3–6 Month Outlook

Expect steady, incremental growth driven by USFDA approvals and focus on injectables. Key risk is pricing pressure and compliance in the US generics market.

Primary Thesis Risk

US generics pricing pressure and compliance risks can derail the entire thesis.

For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.

Returns & Performance

Poor

Return on Equity (ROE)

13.69%

Profit generated per ₹1 of shareholder equity

Poor

Return on Capital (ROCE)

6.90%

Returns generated on total capital deployed

Excellent

Oper. Profit Margin (5Y Avg)

32.80%

Average operating profit margin over 5 years

Good

Dividend Yield

2.39%

Annual dividend as % of current share price

Alembic Ltd Valuation Check

Excellent

Price to Earnings (P/E)

7.95x

Share price ÷ earnings per share. Lower = cheaper

Poor

Industry Avg P/E

35.86x

Average P/E of all peers in this sector

Market-cap Classification
Small-cap
Higher growth potential with higher volatility.

Shareholding Pattern

Excellent

Promoter Holding

70.88%

% shares held by company founders/management

Poor

FII Holding

1.38%

% shares held by foreign institutional investors

Poor

DII Holding

0.05%

% held by domestic mutual funds, LIC, banks

Excellent

Promoter Pledged %

0.00%

% of promoter shares pledged as collateral — lower is safer

Growth Engine

Poor

Profit Growth (Quarterly YoY)

6.17%

Net profit growth vs same quarter last year

Poor

Revenue Growth (Quarterly YoY)

5.58%

Revenue growth vs same quarter last year

Excellent

Revenue Growth (5-Year CAGR)

24.58%

Compounded annual revenue growth over 5 years

Poor

EPS Growth (5-Year CAGR)

-1.12%

Earnings per share growth over 5 years

Poor

Net Profit Growth (5-Year CAGR)

-1.12%

Compounded annual net profit growth over 5 years

Balance Sheet Health

Excellent

Debt to Equity Ratio

0.00x

Total debt ÷ equity. Below 0.5 = financially healthy

Excellent

Interest Coverage Ratio

65.59x

EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably

Free Cash Flow (5-Year Total)

-84.37 (Cr)

Cash left after capex over 5 years. Positive = self-funded growth

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Alembic Ltd Fundamental Analysis & Valuation Benchmarking

Educational evaluation of ALEMBICLTD across key market metrics for learning purposes.

Positive Indicators

7 factors identified

Strong Operating Margins (32.80%)

Observation: Healthy 5-year operating margins indicate pricing power and cost control.

Analysis: OPM >15% suggests operational efficiency and competitive advantages.

Attractive Valuation (P/E: 7.95 vs Industry: 35.86)

Observation: Trading at discount to industry peers.

Analysis: P/E below industry average may present value opportunity.

Consistent Growth Track Record (24.58% CAGR)

Observation: Strong 5-year sales compound annual growth rate.

Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.

Debt-Free Balance Sheet (D/E: 0.00)

Observation: Low leverage provides financial flexibility and reduced risk.

Analysis: Conservative debt structure offers resilience during economic downturns.

Strong Interest Coverage (65.59x)

Observation: Earnings comfortably cover interest obligations.

Analysis: Interest coverage >5x indicates low financial distress risk.

Balanced Promoter Holding (70.88%)

Observation: Optimal balance between promoter control and public float.

Analysis: Promoter holding in 50-75% range provides management alignment.

Zero Share Pledging Risk

Observation: No promoter shares pledged as collateral.

Analysis: Absence of share pledging eliminates potential forced-selling pressure.

Risk Factors

5 factors identified

Suboptimal ROCE (6.90%)

Observation: Returns on capital employed are below expectations.

Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.

Weak Earnings Growth (-1.12% CAGR)

Observation: Below-average 5-year EPS growth performance.

Analysis: Low EPS growth may not keep pace with inflation.

Stagnant Profit Growth (-1.12% CAGR)

Observation: Limited 5-year profit growth trajectory.

Analysis: Low profit growth may indicate scalability challenges or market maturity.

Negative Free Cash Flow (₹-84.37 Cr over 5Y)

Observation: Cash outflows exceed inflows.

Analysis: Negative FCF requires analysis of capital expenditure cycle.

Limited Institutional Interest (FII+DII: 1.43%)

Observation: Low institutional participation may affect liquidity.

Analysis: Limited institutional interest may indicate size constraints or visibility issues.

Alembic Ltd vs Residential, Commercial Projects Peers

Peer Comparison - Residential, Commercial Projects

Compare Alembic Ltd with 10 other companies in the same sector

11 companies
Company Info
Fundamental
Valuation
Profitability
Financial Health
Growth
Dividend
Company
Company name
Score
Bull Run comprehensive fundamental score based on 20+ metrics
Price
Current trading price of the stock
Market Cap
Total value of all shares in the market
P/E
Price per share divided by earnings per share
ROE
Net income divided by shareholder equity
ROCE
Earnings before interest and tax divided by capital employed
Debt/Eq
Total debt divided by total equity
Profit 5Y
Average annual profit growth over 5 years
Sales 5Y
Average annual sales growth over 5 years
Dividend
Annual dividend per share divided by price per share
49/100
91
₹2574.50
8.0
Average
13.69%
Average
6.90%
Poor
0.0
Excellent
-1.12%
Poor
24.58%
Excellent
2.39%
DLF Ltd...
DLF532868
49.2/100
594
₹176317.23
45.7
Average
11.36%
Average
6.51%
Poor
0.0
Excellent
90.95%
Excellent
5.62%
Good
0.84%
31.7/100
1400
₹71505.13
93.4
Average
3.48%
Poor
7.66%
Poor
0.9
Good
4.12%
Average
-1.99%
Poor
0.11%
45.5/100
1789
₹63179.28
40.8
Average
8.98%
Poor
6.57%
Poor
0.9
Good
40.91%
Excellent
15.06%
Excellent
0.00%
62/100
1772
₹61866.27
57.8
Average
9.36%
Poor
10.75%
Average
0.5
Excellent
23.32%
Excellent
14.48%
Good
0.14%
54.3/100
1693
₹58897.53
26.4
Average
14.67%
Average
17.73%
Good
0.2
Excellent
25.94%
Excellent
18.76%
Excellent
0.49%
62.5/100
660
₹21966.91
27.6
Average
14.92%
Average
13.34%
Average
0.8
Good
36.56%
Excellent
14.03%
Good
0.28%
68.1/100
508
₹20611.94
41.8
Average
10.89%
Average
11.17%
Average
0.1
Excellent
73.92%
Excellent
49.46%
Excellent
0.13%
Sobha Ltd...
SOBHA532784
42.9/100
1395
₹16352.79
110.0
Average
2.68%
Poor
6.44%
Poor
0.2
Excellent
-19.57%
Poor
1.47%
Average
0.20%
39/100
801
₹15880.75
204.2
Average
14.72%
Average
5.42%
Poor
3.6
Poor
30.05%
Excellent
59.56%
Excellent
0.00%
0/100
60
₹10648.01
2.53%
Poor
3.19%
Poor
0.5
Excellent
-7.08%
Poor
-7.79%
Poor
0.00%

Alembic Ltd PE Ratio History

Historical price-to-earnings ratio for ALEMBICLTD — last 5 years

YearEPS (₹)Price (₹)P/E Ratio
FY 202512.10₹101.198.4x
FY 202410.46₹131.6612.6x
FY 20237.42₹90.5012.2x
FY 20228.65₹71.208.2x

P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.

Alembic Ltd Dividend History

Annual cash dividends paid by ALEMBICLTD — dividend yield 2.39%

Financial YearDividends Paid (₹ Cr)
FY 202561.17 Cr
FY 202456.23 Cr
FY 202345.92 Cr
FY 20225.15 Cr

Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.

Alembic Ltd Quarterly Performance

Latest quarterly metrics for ALEMBICLTD — revenue growth and profit growth vs same quarter last year

Revenue Growth (YoY)

5.58%

Latest quarter vs same quarter previous year

Net Profit Growth (YoY)

6.17%

Latest quarter net profit vs same quarter previous year

5-Year Revenue CAGR

24.58%

Compounded annual revenue growth over 5 years

5-Year Profit CAGR

-1.12%

Compounded annual net profit growth over 5 years

Alembic Ltd Technical Indicators

SMA 50, SMA 200, RSI and volume signals for ALEMBICLTD — calculated from daily price history

23RSI 14
Oversold — RSI 23

Selling pressure is heavy — potential reversal zone.

SMA 50
86
▲ Price above SMA 50 — Short-term bullish
SMA 200
97
▼ Price below SMA 200 — Long-term downtrend
30-Day Avg Volume
233K shares/day
Average daily traded volume over last 30 trading sessions

Technical indicators are for educational purposes only. Not investment advice.

Alembic Ltd Financial Statements

Annual income statement, balance sheet and cash flow for Alembic Ltd (ALEMBICLTD) — sourced from NSE/BSE filings.

Loading Financial Statements...

Fetching financial data for Alembic Ltd

About ALEMBICLTD (Alembic Ltd)

Alembic Ltd is a dynamic force reshaping the landscape of Indian real estate, crafting vibrant residential communities and strategically designed commercial spaces. The company's r...esidential portfolio is distinguished by its commitment to creating homes that resonate with modern lifestyles, blending aesthetic appeal with functional design. From spacious apartments bathed in natural light to meticulously planned villas offering privacy and tranquility, Alembic Ltd focuses on fostering a sense of community and well-being for its residents. Attention to detail is paramount, with high-quality materials, lush landscaping, and thoughtful amenities integrated seamlessly into each project. The aim is not just to build houses, but to cultivate havens where families can thrive and create lasting memories. On the commercial front, Alembic Ltd develops innovative and adaptable workspaces that cater to the evolving needs of businesses. These projects are more than just buildings; they are catalysts for collaboration, productivity, and growth. Prioritizing strategic locations and intelligent infrastructure, Alembic's commercial properties offer a competitive edge to tenants. State-of-the-art facilities, flexible floor plans, and sustainable design principles are hallmarks of their approach. Understanding the importance of image, Alembic Ltd creates prestigious business addresses that project professionalism and inspire confidence. Whether it's a cutting-edge office complex or a retail hub designed to attract customers, their projects are tailored to maximize value for businesses and investors alike. Beyond construction, Alembic Ltd offers comprehensive real estate solutions, providing project management and marketing consultancy services to ensure successful project outcomes. This end-to-end approach, coupled with a commitment to transparency and integrity, has earned them a reputation as a trusted partner in the industry. Furthermore, Alembic Ltd strategically leases commercial properties, providing a stable income stream and further solidifying their position in the real estate market. The company also continues to engage in research and development, not only within their pharmaceutical division but also exploring innovative construction techniques and sustainable building materials that will shape the future of their real estate endeavors.

Company Details

Symbol:ALEMBICLTD
Industry:Residential, Commercial Projects
Sector:Residential, Commercial Projects

Key Leadership

Ms. Malika Chirayu Amin
MD, CEO & Executive Director
Mr. Udit C. Amin
MD & Director
Mr. Rasesh Shah
Chief Financial Officer

Corporate Events

Recent
Ex-Dividend Date

ALEMBICLTD Share Price: Frequently Asked Questions

What is the current share price of Alembic Ltd?

Alembic Ltd (ALEMBICLTD) trades at ₹90.79 on NSE and BSE. Market cap ₹2.57K (Cr). Educational data only.

What is the P/E ratio of Alembic Ltd?

Alembic Ltd has a P/E of 7.95x vs industry average 35.86x.

What is the Bull Run score for Alembic Ltd?

Alembic Ltd has a Bull Run score of 49/100 based on 25+ financial parameters.

Does Alembic Ltd pay dividends?

Alembic Ltd has a dividend yield of 2.39%. Past dividends don't guarantee future payments.

What is the ROE of Alembic Ltd?

Alembic Ltd has ROE of 13.69%. Higher ROE indicates better use of shareholder equity.

What is the debt-to-equity ratio of Alembic Ltd?

Alembic Ltd has debt-to-equity of 0.00.

Is Alembic Ltd a good investment?

Bull Run gives Alembic Ltd a score of 49/100. This is not investment advice — consult a SEBI-registered advisor.